| Year |
Citation |
Score |
| 2014 |
Casablanca Y, Mieznikowski J, Day R, Hamilton CA, Conrads TP, Maxwell GL, Hood BL, Wallace A, Rose GS, McMeekin DS. Molecular profiling of tumors from stage I versus stage III/IV cancer patients: A prediction signature for metastasis in Gynecologic Oncology Group 8024 Gynecologic Oncology. 133: 6. DOI: 10.1016/J.Ygyno.2014.03.031 |
0.353 |
|
| 2013 |
Risinger JI, Allard J, Chandran U, Day R, Chandramouli GV, Miller C, Zahn C, Oliver J, Litzi T, Marcus C, Dubil E, Byrd K, Cassablanca Y, Becich M, Berchuck A, et al. Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion. Frontiers in Oncology. 3: 139. PMID 23785665 DOI: 10.3389/Fonc.2013.00139 |
0.325 |
|
| 2009 |
Wang M, Day R. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity. Journal of Biopharmaceutical Statistics. 20: 125-144. PMID 20077253 DOI: 10.1080/10543400903280613 |
0.303 |
|
| 2005 |
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunology, Immunotherapy : Cii. 54: 254-64. PMID 15372205 DOI: 10.1007/S00262-004-0581-1 |
0.331 |
|
| 2004 |
Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Investigation. 22: 858-65. PMID 15641483 DOI: 10.1081/Cnv-200039645 |
0.351 |
|
| 2004 |
Shackney SE, Smith CA, Pollice A, Brown K, Day R, Julian T, Silverman JF. Intracellular Patterns of Her-2/neu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Postoperative Clinical Disease-Free Survival Clinical Cancer Research. 10: 3042-3052. PMID 15131041 DOI: 10.1158/1078-0432.Ccr-0401-3 |
0.346 |
|
| 2004 |
Welsh C, Day R, McGurk C, Masters JR, Wood RD, Köberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. International Journal of Cancer. 110: 352-61. PMID 15095299 DOI: 10.1002/Ijc.20134 |
0.305 |
|
| 2004 |
Ramalingam S, Belani CP, Day R, Zamboni BA, Jacobs SA, Jett JR. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 15: 247-51. PMID 14760117 DOI: 10.1093/Annonc/Mdh061 |
0.359 |
|
| 2001 |
Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and ζ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma Cancer. 91: 2136-2147. PMID 11391595 DOI: 10.1002/1097-0142(20010601)91:11<2136::Aid-Cncr1242>3.0.Co;2-Q |
0.32 |
|
| 1997 |
Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology. 39: 349-56. PMID 9025776 DOI: 10.1007/S002800050582 |
0.303 |
|
| 1991 |
Vlock DR, Johnson J, Myers E, Day R, Gooding WE, Whiteside T, Pelch K, Sigler B, Wagner R, Colao D, Rust D. Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head and Neck-Journal For the Sciences and Specialties of the Head and Neck. 13: 15-21. PMID 1989925 DOI: 10.1002/Hed.2880130103 |
0.34 |
|
| Show low-probability matches. |